Latest Content

Patients with myasthenia gravis (MG) had greater morbidity and extended hospitalization when they underwent cardiac surgery.

Advances in sickle cell therapies, including gene editing, offer hope—but racial disparities, cost, and access barriers remain major challenges.

Today's approval enables once-monthly SC amivantamab dosing for patients with EGFR-mutant NSCLC, reducing clinic visits without compromising efficacy or safety.

Experts at a roundtable in Boston, Massachusetts, on November 19, 2025, discussed multidisciplinary strategies for obesity care, including systemic and operational barriers and scalable solutions to promote patient ownership.

New bipartisan legislation extends key health care programs and tightens oversight of PBMs in Medicare Part D and commercial markets, but impacts on drug costs will not be immediate.

Penetration of Medicare Shared Savings Program accountable care organizations and Medicare Advantage was not associated with substantive changes in health care use among commercial enrollees.

Kohei Shitara, MD, discusses CLDN18.2-guided therapy, nivolumab plus zolbetuximab, and toxicity management in advanced gastric and gastroesophageal cancers.

The FDA granted sibeprenlimab accelerated approval for nephropathy after data showed it cut IgA nephropathy proteinuria by about 50% via APRIL inhibition.

These new data show that 64.8% of US adults take at least 1 prescription medication each year.